- July 18, 2008
- Taiho Pharmaceutical Co., Ltd.
License agreement with Sanofi-Aventis on TS-1 is terminated
Taiho announces today that sanofi-aventis is returning its territory rights to Taiho Pharmaceutical Co., Ltd. for the development and commercialization of the oral anti-cancer agent S-1.
Taiho will pursue further development of S-1 outside of Japan with gastric cancer included.
About S-1
S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.
S-1 has been commercialized in Japan by Taiho Pharmaceuticals since 1999 for the treatment of gastric, colorectal, head and neck, non-small cell lung, metastatic breast, pancreas and biliary tract cancers.
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.